Comparison of the prevalence of insulin resistance between the HCV Antibody positive and non-infected examinee.
- Author:
Jae Ho JANG
1
;
Hong Joo KIM
;
Jung Ho PARK
;
Dong Il PARK
;
Yong Kyun CHO
;
Chong Il SOHN
;
Woo Kyu JEON
;
Byung Ik KIM
Author Information
1. Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. hongjoo3.kim@samsung.com
- Publication Type:Original Article
- Keywords:
Insulin resistance;
Hepatic steatosis;
Chronic hepatitis C;
Fasting glucose level;
Body mass index
- MeSH:
Blood Glucose;
Body Mass Index;
Diabetes Mellitus;
Fasting;
Hepatitis B virus;
Hepatitis C, Chronic;
Homeostasis;
Humans;
Hyperinsulinism;
Insulin;
Insulin Resistance;
Korea;
Prevalence;
Viruses
- From:Korean Journal of Medicine
2010;79(4):381-386
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Considerable evidence indicates that patients with chronic hepatitis C virus (HCV) infection have a greater risk of developing insulin resistance (IR) compared with non-infected individuals or patients with hepatitis B virus (HBV) infection. Few reports have examined the prevalence of IR and hepatic steatosis in patients with chronic HCV infection in Korea. METHODS: Ninety subjects positive for HCV antibody who had normal fasting blood glucose levels and no history of diabetes mellitus were compared with 271 HCV non-infected, age- and sex-matched, healthy examinees between January 2005 and December 2006. RESULTS: No significant differences in the body mass index (BMI) and fasting blood glucose level were found between the anti-HCV-antibody-positive and non-infected groups. The serum fasting insulin level was significantly higher in the HCV-antibody- positive group than in the non-infected group (9.11+/-2.94 vs. 8.43+/-2.70 microU/mL (mean+/-SD), p=0.04). Although the homeostasis model assessment of insulin resistance (HOMA-IR) was not significantly different between the two groups (2.035+/-0.69 vs. 1.899+/-0.64, p=0.088), the prevalence of insulin resistance (HOMA-IR> or =2.7) was significantly higher in the anti-HCV positive group (18.9% vs. 10.3%, p=0.042). Hepatic steatosis identified by transabdominal ultrasonography was significantly more frequent in the non-infected group (20.3% vs. 11.1%, p=0.028). CONCLUSIONS: The anti-HCV positive subjects had significant hyperinsulinemia and a higher prevalence of insulin resistance than the non-infected group, whereas hepatic steatosis was more frequent in the non-infected group.
